A Randomized, Double Blind, Placebo Controlled, Phase III Study of KUC-7483 in Patients With Overactive Bladder.

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Phase III Study of KUC-7483 in Patients With Overactive Bladder.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2010

At a glance

  • Drugs Ritobegron; Tolterodine
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Kissei Pharmaceutical
  • Most Recent Events

    • 26 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Interim results released in a Kissei Pharmaceuticals media release. The company intends to perform a detailed analysis prior to making a decision regarding further development of KUC 7483.
    • 02 Jul 2010 Primary endpoint 'Micturition rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top